Regulatory Update on DrugSorb-ATR by CytoSorbents
CytoSorbents Corporation (NASDAQ: CTSO), recognized for its innovative blood purification therapies, has recently provided an essential regulatory update regarding the DrugSorb™-ATR. This groundbreaking device is designed to help reduce bleeding during coronary artery bypass grafting (CABG) surgery, specifically for patients who have recently stopped taking Brilinta® (ticagrelor). The latest announcements from both the U.S. FDA and Health Canada highlight the ongoing progress and challenges faced in bringing this critical technology to market.
FDA Appeal Hearing Scheduled
On June 27, the FDA communicated the scheduling of an appeal hearing concerning the supervisory review requested by CytoSorbents. This appeal is particularly relevant following the De Novo Denial Letter received on April 25, which indicated certain deficiencies in the company’s submission needing resolution before approval could be granted. The supervisory review represents a valuable opportunity for engaging directly with FDA senior leadership, and both CytoSorbents and its external experts are focusing on concluding this process by the end of the year.
Health Canada’s Notice and Reconsideration Process
Health Canada, on June 26, issued a Notice of Refusal regarding the Medical Device License application for DrugSorb-ATR, highlighting non-compliance with specific Medical Device Regulations. In response, CytoSorbents is set to submit a Request for Reconsideration, reinforcing their commitment to addressing the concerns raised. This process allows for a direct appeal to different Health Canada staff members who were not involved in the initial review and promises to integrate external expert insights.
Expectations and Commitment to Innovation
Dr. Phillip Chan, CEO of CytoSorbents, expressed strong optimism about DrugSorb-ATR's potential impact. He emphasized that this device meets a vital need in cardiac surgery by lessening the risk of severe bleeding among patients using antiplatelet drugs. With no existing approved alternatives in the U.S. and Canada, the necessity for DrugSorb-ATR is increasingly evident. The company remains dedicated to navigating the regulatory landscape expediently, hoping to provide surgeons and patients access to this innovative solution soon.
About CytoSorbents Corporation
CytoSorbents Corporation (NASDAQ: CTSO) specializes in blood purification technologies that target life-threatening conditions in intensive care and cardiac surgery environments. Their proprietary technology utilizes biocompatible polymer beads capable of deferring toxic substances from the blood via active filtration methods. The success of products like CytoSorb has paved the way for new protocols aimed at enhancing patient safety and outcomes during critical procedures.
Product Development and FDA Breakthrough Designation
The journey of CytoSorb-ATR is part of a larger commitment to develop cutting-edge medical devices. The company is not only focused on DrugSorb-ATR but has also received FDA Breakthrough Device Designations for its innovations aimed at anticoagulant removal during cardiopulmonary bypass procedures. The intention is to significantly improve surgical safety and expand the availability of life-saving treatments.
Company’s Future Steps
As CytoSorbents works through the regulatory challenges, it continues to showcase its commitment to medical advancements that can save lives. The ongoing engagement with both the FDA and Health Canada demonstrates a proactive approach to resolving regulatory hurdles, ultimately leading to a future where patients at risk can benefit from these advanced medical therapies.
Frequently Asked Questions
What is DrugSorb-ATR?
DrugSorb-ATR is a medical device under development by CytoSorbents designed to reduce perioperative bleeding in patients undergoing CABG surgery while on the blood thinner ticagrelor.
What updates have been provided regarding FDA approvals?
The FDA has scheduled an appeal hearing for CytoSorbents regarding a supervisory review of their Device request, with expectations for resolution by year-end.
How has Health Canada responded to CytoSorbents' applications?
Health Canada issued a Notice of Refusal for the Medical Device License application for DrugSorb-ATR, prompting the company to file a Request for Reconsideration.
What significant challenges does CytoSorbents face in the approval process?
Key challenges include addressing deficiencies outlined in the FDA's denial letter and ensuring compliance with Health Canada's regulations.
What is the significance of DrugSorb-ATR?
This device addresses critical needs in cardiac surgery where patients require blood thinners, a demographic currently underserved by existing therapies.
